NCT00286455 - Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

329

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions

Diabetes Mellitus

Interventions

DRUG

Alogliptin

Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Alogliptin

Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Placebo

Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.

Trial Locations (67)

Unknown

Birmingham

Peoria

Phoenix

Anaheim

Artesia

Fresno

Lafayette

Northridge

Orange

San Diego

Walnut Creek

Colorado Springs

Denver

Washington D.C.

Cocoa Beach

Kissimmee

Longwood

Ocala

Ocoee

Saint Cloud

Honolulu

Idaho Falls

Avon

Elkhart

Evansville

Baltimore

Sudbury

St Louis

Omaha

Berlin

Burlington

Morehead City

Pinehurst

Winston-Salem

Cincinnati

Tulsa

Lansdale

West Grove

Charleston

Columbia

Simpsonville

Bristol

Cookeville

Milan

Corpus Christi

Dallas

San Antonio

Temple

Texarkana

Burlington

Multiple Cities